At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Compare Efficacy, Safety, and Tolerability of KN046 Combined With Lenvatinib Versus Docetaxel in Subjects With Non-Small Cell Lung Cancer After Failure of Anti-PD-(L)1 Agent
In Brief
A Phase 3 clinical trial evaluating KN046, Lenvatinib, and 1 other intervention for Advanced Non-small Cell Lung Cancer. Terminated early, enrolled 16 participants across 1 site.
Signals
Detailed Summary
This is a phase 2/3, multicenter, randomized, open, positive-controlled study of patients with advanced non-small cell lung cancer whose disease has progressed after prior anti-PD-(L)1 therapy. Subjects should have documented progressive disease during prior treatment with first- or second-line PD-(L)1 and platinum-containing dual-agent chemotherapy.Subjects will be randomized to two treatment groups in a 1:1 ratio. Treatment Group: KN046 5mg/kg Q3W + lenvatinib recommended for phase III dose (RP3D) every day. Control group: Docetaxel 75mg/m2 Q3W .
Study Details
Timeline
Interventions
KN046 is 5 milligram per kilogram, every 3 weeks.
Lenvatinib is RP3D milligram per day, every day.
Docetaxel is 75 milligram per Square meter, every 3 weeks.